Target Price | $10.00 |
Price | $1.84 |
Potential |
443.48%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Outlook Therapeutics, Inc. 2026 .
The average Outlook Therapeutics, Inc. target price is $10.00.
This is
443.48%
register free of charge
$21.00
1,041.30%
register free of charge
$3.00
63.04%
register free of charge
|
|
A rating was issued by 4 analysts: 3 Analysts recommend Outlook Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Outlook Therapeutics, Inc. stock has an average upside potential 2026 of
443.48%
register free of charge
|
Sep '24 |
2025 Estimates |
|
---|---|---|
EV/Sales | 16.07 |
Outlook Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Ascendiant Capital |
Locked
➜
Locked
|
Locked | Jun 06 2025 |
Ascendiant Capital |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Jan 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 17 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
Analyst Rating | Date |
---|---|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Jun 06 2025 |
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Feb 18 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 18 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Jan 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 17 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Dec 02 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.